Cuprina Holdings (NASDAQ: CUPR) has announced the appointment of Dr. Ronald Sherman, a leading innovator in maggot debridement therapy (MDT), as medical and scientific director, effective September 2025—securing the license for Dr. Sherman’s FDA-cleared Lucilia sericata medical maggots.
According to a June 2025 study by Research and Markets, the US market for maggot debridement therapy in 2024 was valued at $13.9 million, and was projected to grow at a CAGR of 10.1 percent to reach a value of $24.8 million by 2030.
In a statement, David Quek, CEO of Cuprina, commented, “We are thrilled to join forces with Dr. Sherman. Not only will Ron provide our company with unparalleled clinical expertise and regulatory affairs guidance for our medical maggot therapies, he will also collaborate with Cuprina to develop a structured training and certification framework for bio-therapeutics—an initiative we believe will further our goal of educating clinicians to increase their adoption rate of MDT globally.”
Mr. Quek added that Cuprina is currently updating its own FDA submission for the use of another species of medical maggots, Lucilia cuprina. Upon receiving marketing clearance—which could come within 90 business days—Cuprina would hold two U.S. FDA clearances for individual maggot species in MDT.
